Authors:
,
, and
Mathew L. Nguyen
Mathew L. Nguyen
Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Florida, Gainesville, FL, USA
Search for other papers by Mathew L. Nguyen in
Current site
Google Scholar
PubMed
Search for other papers by Mathew L. Nguyen in
Current site
Google Scholar
PubMed
Michael A. Shapiro
Michael A. Shapiro
Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Florida, Gainesville, FL, USA
Department of Psychiatry, University of Florida, PO Box 100234, Gainesville, FL, 32610, USA
Search for other papers by Michael A. Shapiro in
Current site
Google Scholar
PubMed
Department of Psychiatry, University of Florida, PO Box 100234, Gainesville, FL, 32610, USA
Search for other papers by Michael A. Shapiro in
Current site
Google Scholar
PubMed
Stephen J. Welch
Stephen J. Welch
UF Forensic Institute, Department of Psychiatry, University of Florida, Gainesville, FL, USA
Search for other papers by Stephen J. Welch in
Current site
Google Scholar
PubMed
Search for other papers by Stephen J. Welch in
Current site
Google Scholar
PubMed
Abstract
Background: The initial treatment of obsessive-compulsive disorder (OCD) has generally been limited to serotonergic agents, cognitive-behavioral therapy (CBT), or a combination of the two. These findings were supported by the POTS study for OCD in children and adolescents. However, treatment with serotonergic agents or CBT can take several weeks before benefit is seen; severe cases of OCD may require more immediate treatment. Case report: The authors present a case of severe OCD in an adolescent that required immediate treatment due to her critical medical condition. The patient's symptoms included not eating or taking medications or fluids by mouth due to fears of contamination. A medical hospitalization was previously required due to dehydration. As treatment with an SSRI would not have quick enough onset and the patient was initially resistant to participating in CBT, the patient was psychiatrically hospitalized and first started on liquid risperidone. After several doses of risperidone, the patient was able to participate in CBT and start sertraline. Discussion: The authors discuss the differential diagnosis of such a patient, including the continuum of OCD symptoms and psychotic symptoms. The authors discuss the different treatment options, including the utilization of inpatient psychiatric hospitalization. The authors discuss the potential risks and benefits of using atypical antipsychotics in lieu of benzodiazepines for the initial treatment of severe adolescent OCD. The authors also discuss other current treatment recommendations and rationale for the treatment that was pursued. Conclusions: This patient received benefit of her symptoms relatively quickly with psychiatric hospitalization and an atypical antipsychotic. The diagnosis of a psychotic disorder should be considered. These treatment options must be weighed against the risks of atypical antipsychotics, including extrapyramidal symptoms, weight gain, and metabolic syndrome; benzodiazepines also have their risks and benefits. Additionally, the cost of time and finances of inpatient hospitalization must be considered. More research is needed regarding the short- and long-term efficacy and safety of antipsychotics in the treatment of OCD in the child and adolescent population.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
APA 2000 Diagnostic and statistical manual of mental disorders 4th ed. Author Washington, DC.
-
A. Attard G. Ranjith D. Taylor 2008 Delirium and its treatment CNS Drugs 22 631 644.
-
S. Bellino L. Patria S. Ziero F. Bogetto 2005 Clinical picture of obsessive-compulsive disorder with poor insight: A regression model Psychiatry Research 136 223 231.
-
R. Bergeron A. V. Ravindran Y. Chaput E. Goldner R. Swinson M. A. van Ameringen C. Austin V. Hadrava 2002 Sertraline and fluoxetine treatment of obsessive-compulsive disorder: Results of a double-blind, 6-month treatment study Journal of Clinical Psychopharmacology 22 2 148 154.
-
J. Biederman 1990 The diagnosis and treatment of adolescent anxiety disorders Journal of Clinical Psychiatry 51 Suppl20–6 50 53.
-
T. Björgvinsson C. T. Wetterneck D. M. Powell G. S. Chasson S. A. Webb J. Hart S. Heffelfinger R. Azzouz T. L. Entricht J. E. Davidson M. A. Stanley 2008 Treatment outcome for adolescent obsessive-compulsive disorder in a specialized hospital setting Journal of Psychiatric Practice 14 137 145.
-
M. H. Bloch A. Landeros-Weisenberger B. Kelmendi V. Coric M. B. Bracken J. F. Leckman 2006 A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder Molecular Psychiatry 11 7 622 632.
-
J. A. Bodkin K. White 1989 Clonazepam in the treatment of obsessive-compulsive disorder associated with panic disorder in one patient Journal of Clinical Psychiatry 50 265 266.
-
B. A. Crockett E. Churchill J. R. Davidson 2004 A double-blind combination study of clonazepam with sertraline for obsessive-compulsive disorder Annals of Clinical Psychiatry 16 127 132.
-
E. H. Decloedt D. J. Stein 2010 Current trends in drug treatment of obsessive-compulsive disorder Neuropsychiatric Disease and Treatment 6 233 242.
-
D. Denys J. Zohar H. G. Westenberg 2004 The role of dopamine in obsessive-compulsive disorder: Preclinical and clinical evidence Journal of Clinical Psychiatry 65 Suppl14 11 17.
-
D. D. Dougherty S. L. Rauch M. A. Jenike 2004 Pharmacotherapy for obsessive-compulsive disorder J. Clin. Psychol. 60 11 1195 1202.
-
K. Gao D. Muzina P. Gajwani J. R. Calabrese 2006 Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: A review Journal of Clinical Psychiatry 67 1327 1340.
-
R. B. Goldstein E. A. Storch H. Lehmkuhl G. R. Geffken W. K. Goodman T. K. Murphy 2009 Successful medication withdrawal after cognitive-behavioral therapy in a treatment-resistant preadolescent male with obsessive-compulsive disorder Depression and Anxiety 26 E23 E25.
-
M. A. Grados M. A. Riddle 2001 Pharmacological treatment of childhood obsessive-compulsive disorder: From theory to practice Journal of Clinical Child Psychology 30 67 79.
-
E. Hollander A. Kaplan S. M. Stahl 2003 A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder World Journal of Biological Psychiatry 4 30 34.
-
Ipser, J. C., Stein, D. J., Hawkridge, S. & Hoppe, L. (2009). Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database of Systematic Reviews, July 8 2009(3), CD005170.
-
M. J. Kozak E. B. Foa 1994 Obsessions, overvalued ideas, and delusions in obsessive-compulsive disorder Behaviour Research and Therapy 32 343 353.
-
R. A. Lorenz C. W. Jackson M. Saitz 2010 Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder Pharmacotherapy 30 942 951.
-
G. Masi S. Millepiedi G. Perugi C. Pfanner S. Berloffa C. Pari M. Mucci 2009 Pharmacotherapy in paediatric obsessive-compulsive disorder: A naturalistic, retrospective study CNS Drugs 23 241 252.
-
C. J. McDougle C. N. Epperson G. H. Pelton S. Wasylink L. H. Price 2000 A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder Archives of General Psychiatry 57 794 801.
-
J. Mendels T. F. Krajewski V. Huffer R. J. Taylor S. Secunda A. Schless J. A. Sebastian G. Semchyshyn M. J. Durr A. S. Melmed A. Whyte 1986 Effective short-term treatment of generalized anxiety disorder with trifluoperazine Journal of Clinical Psychiatry 47 170 174.
-
J. R. Nash D. J. Nutt 2005 Pharmacotherapy of anxiety Handbook of Experimental Pharmacology 169 469 501.
-
T. A. Niendam J. Berzak T. D. Cannon C. E. Bearden 2009 Obsessive compulsive symptoms in the psychosis prodrome: Correlates of clinical and functional outcome Schizophrenia Research 108 170 175.
-
M. W. Otto S. E. Bruce T. Deckersbach 2005 Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: Issues in the treatment of a patient in need Journal of Clinical Psychiatry 66 Suppl2 34 38.
-
M. Perez de la Mora A. Gallegos-Cari Y. Arizmendi-Garcia D. Marcellino K. Fuxe 2010 Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: Structural and functional analysis Progress in Neurobiology 90 198 216.
-
M. A. Pezze J. Feldon 2004 Mesolimbic dopaminergic pathways in fear conditioning Progress in Neurobiology 74 301 320.
-
POTS 2004 Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder Journal of the American Medical Association 292 1969 1976.
-
L. N. Ravindran S. M. Jung A. V. Ravindran 2010 Intravenous anti-obsessive agents: A review Journal of Psychopharmacology 24 287 296.
-
S. P. Reinblatt J. T. Walkup 2005 Psychopharmacologic treatment of pediatric anxiety disorders Child and Adolescent Psychiatric Clinics of North America 14 877 908.
-
M. F. Rodowski C. C. Cagande M. A. Riddle 2008 Childhood obsessive-compulsive disorder presenting as schizophrenia spectrum disorders Journal of Child and Adolescent Psychopharmacology 18 395 401.
-
L. Scahill R. D. Walker S. N. Lechner K. E. Tynan 1993 Inpatient treatment of obsessive-compulsive disorder in childhood: A case study J. Child. Adolesc. Psychiatr. Ment. Health Nurs. 6 3 5 14.
-
G. Shoval G. Zalsman L. Sher A. Apter A. Weizman 2006 Clinical characteristics of inpatient adolescents with severe obsessive-compulsive disorder Depression and Anxiety 23 62 70.
-
J. G. Simeon H. B. Ferguson 1987 Alprazolam effects in children with anxiety disorders Canadian Journal of Psychiatry 32 570 574.
-
G. E. Tesar M. A. Jenike 1984 Alprazolam as treatment for a case of obsessive-compulsive disorder American Journal of Psychiatry 141 689 690.
-
P. H. Thomsen 1998 Obsessive-compulsive disorder in children and adolescents: Clinical guidelines European Child and Adolescent Psychiatry 7 1 11.
-
P. H. Thomsen 2004 Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: A case series Annals of Clinical Psychiatry 16 201 207.
-
S. Tumkaya F. Karadag N. K. Oguzhanoglu C. Tekkanat G. Varma O. Ozdel et al.2009 Schizophrenia with obsessive-compulsive disorder and obsessive-compulsive disorder with poor insight: A neuropsychological comparison Psychiatry Research 165 38 46.
-
H. G. M. Westenberg N. A. Fineberg D. Denys 2007 Neurobiology of obsessive-compulsive disorder: Serotonin and beyond CNS Spectrums 12 2Suppl3 14 27.
-
H. A. Westra S. H. Stewart B. E. Conrad 2002 Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia Journal of Anxiety Disorders 16 233 246.
-
M. W. Witek V. Rojas C. Alonso H. Minami R. R. Silva 2005 Review of benzodiazepine use in children and adolescents Psychiatric Quarterly 76 283 296.
Please, download the file from HERE
Dr. Zsolt Demetrovics
Institute of Psychology, ELTE Eötvös Loránd University
Address: Izabella u. 46. H-1064 Budapest, Hungary
Phone: +36-1-461-2681
E-mail: jba@ppk.elte.hu
Indexing and Abstracting Services:
- Web of Science [Science Citation Index Expanded (also known as SciSearch®)
- Journal Citation Reports/Science Edition
- Social Sciences Citation Index®
- Journal Citation Reports/ Social Sciences Edition
- Current Contents®/Social and Behavioral Sciences
- EBSCO
- GoogleScholar
- PsycINFO
- PubMed Central
- SCOPUS
- Medline
- CABI
- CABELLS Journalytics
| 2022 | |
|---|---|
| Web of Science | |
| Total Cites WoS |
5713 |
| Journal Impact Factor | 7.8 |
| Rank by Impact Factor |
Psychiatry (SCIE) 18/155 |
| Impact Factor without Journal Self Cites |
7.2 |
| 5 Year Impact Factor |
8.9 |
| Journal Citation Indicator | 1.42 |
| Rank by Journal Citation Indicator |
Psychiatry 35/264 |
| Scimago | |
| Scimago H-index |
69 |
| Scimago Journal Rank |
1.918 |
| Scimago Quartile Score | Clinical Psychology Q1 Medicine (miscellaneous) Q1 Psychiatry and Mental Health Q1 |
| Scopus | |
| Scopus Cite Score |
11.1 |
| Scopus Cite Score Rank |
Clinical Psychology 10/292 (96th PCTL) Psychiatry and Mental Health 30/531 (94th PCTL) Medicine (miscellaneous) 25/309 (92th PCTL) |
| Scopus SNIP |
1.966 |
| 2021 | |
|---|---|
| Web of Science | |
| Total Cites WoS |
5223 |
| Journal Impact Factor | 7,772 |
| Rank by Impact Factor | Psychiatry SCIE 26/155 Psychiatry SSCI 19/142 |
| Impact Factor without Journal Self Cites |
7,130 |
| 5 Year Impact Factor |
9,026 |
| Journal Citation Indicator | 1,39 |
| Rank by Journal Citation Indicator |
Psychiatry 34/257 |
| Scimago | |
| Scimago H-index |
56 |
| Scimago Journal Rank |
1,951 |
| Scimago Quartile Score | Clinical Psychology (Q1) Medicine (miscellaneous) (Q1) Psychiatry and Mental Health (Q1) |
| Scopus | |
| Scopus Cite Score |
11,5 |
| Scopus CIte Score Rank |
Clinical Psychology 5/292 (D1) Psychiatry and Mental Health 20/529 (D1) Medicine (miscellaneous) 17/276 (D1) |
| Scopus SNIP |
2,184 |
| 2020 | |
| Total Cites | 4024 |
| WoS | |
| Journal Impact Factor |
6,756 |
| Rank by | Psychiatry (SSCI) 12/143 (Q1) |
| Impact Factor | Psychiatry 19/156 (Q1) |
| Impact Factor | 6,052 |
| without | |
| Journal Self Cites | |
| 5 Year | 8,735 |
| Impact Factor | |
| Journal | 1,48 |
| Citation Indicator | |
| Rank by Journal | Psychiatry 24/250 (Q1) |
| Citation Indicator | |
| Citable | 86 |
| Items | |
| Total | 74 |
| Articles | |
| Total | 12 |
| Reviews | |
| Scimago | 47 |
| H-index | |
| Scimago | 2,265 |
| Journal Rank | |
| Scimago | Clinical Psychology Q1 |
| Quartile Score | Psychiatry and Mental Health Q1 |
| Medicine (miscellaneous) Q1 | |
| Scopus | 3593/367=9,8 |
| Scite Score | |
| Scopus | Clinical Psychology 7/283 (Q1) |
| Scite Score Rank | Psychiatry and Mental Health 22/502 (Q1) |
| Scopus | 2,026 |
| SNIP | |
| Days from | 38 |
| submission | |
| to 1st decision | |
| Days from | 37 |
| acceptance | |
| to publication | |
| Acceptance | 31% |
| Rate |
| 2019 | |
|---|---|
| Total Cites WoS |
2 184 |
| Impact Factor | 5,143 |
| Impact Factor without Journal Self Cites |
4,346 |
| 5 Year Impact Factor |
5,758 |
| Immediacy Index |
0,587 |
| Citable Items |
75 |
| Total Articles |
67 |
| Total Reviews |
8 |
| Cited Half-Life |
3,3 |
| Citing Half-Life |
6,8 |
| Eigenfactor Score |
0,00597 |
| Article Influence Score |
1,447 |
| % Articles in Citable Items |
89,33 |
| Normalized Eigenfactor |
0,7294 |
| Average IF Percentile |
87,923 |
| Scimago H-index |
37 |
| Scimago Journal Rank |
1,767 |
| Scopus Scite Score |
2540/376=6,8 |
| Scopus Scite Score Rank |
Cllinical Psychology 16/275 (Q1) Medicine (miscellenous) 31/219 (Q1) Psychiatry and Mental Health 47/506 (Q1) |
| Scopus SNIP |
1,441 |
| Acceptance Rate |
32% |
| Journal of Behavioral Addictions | |
|---|---|
| Publication Model | Gold Open Access |
| Submission Fee | none |
| Article Processing Charge | 990 EUR/article for articles submitted after 30 April 2023 (850 EUR for articles submitted prior to this date) |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%. |
| Subscription Information | Gold Open Access |
| Journal of Behavioral Addictions | |
|---|---|
| Language | English |
| Size | A4 |
| Year of Foundation |
2011 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Eötvös Loránd Tudományegyetem |
| Founder's Address |
H-1053 Budapest, Hungary Egyetem tér 1-3. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 2062-5871 (Print) |
| ISSN | 2063-5303 (Online) |
Senior editors
Editor(s)-in-Chief: Zsolt DEMETROVICS
Assistant Editor(s): Csilla ÁGOSTON
Associate Editors
- Stephanie ANTONS (Universitat Duisburg-Essen, Germany)
- Joel BILLIEUX (University of Lausanne, Switzerland)
- Beáta BŐTHE (University of Montreal, Canada)
- Matthias BRAND (University of Duisburg-Essen, Germany)
- Ruth J. van HOLST (Amsterdam UMC, The Netherlands)
- Daniel KING (Flinders University, Australia)
- Gyöngyi KÖKÖNYEI (ELTE Eötvös Loránd University, Hungary)
- Ludwig KRAUS (IFT Institute for Therapy Research, Germany)
- Marc N. POTENZA (Yale University, USA)
- Hans-Jurgen RUMPF (University of Lübeck, Germany)
Editorial Board
- Max W. ABBOTT (Auckland University of Technology, New Zealand)
- Elias N. ABOUJAOUDE (Stanford University School of Medicine, USA)
- Hojjat ADELI (Ohio State University, USA)
- Alex BALDACCHINO (University of Dundee, United Kingdom)
- Alex BLASZCZYNSKI (University of Sidney, Australia)
- Judit BALÁZS (ELTE Eötvös Loránd University, Hungary)
- Kenneth BLUM (University of Florida, USA)
- Henrietta BOWDEN-JONES (Imperial College, United Kingdom)
- Wim VAN DEN BRINK (University of Amsterdam, The Netherlands)
- Gerhard BÜHRINGER (Technische Universität Dresden, Germany)
- Sam-Wook CHOI (Eulji University, Republic of Korea)
- Damiaan DENYS (University of Amsterdam, The Netherlands)
- Jeffrey L. DEREVENSKY (McGill University, Canada)
- Naomi FINEBERG (University of Hertfordshire, United Kingdom)
- Marie GRALL-BRONNEC (University Hospital of Nantes, France)
- Jon E. GRANT (University of Minnesota, USA)
- Mark GRIFFITHS (Nottingham Trent University, United Kingdom)
- Anneke GOUDRIAAN (University of Amsterdam, The Netherlands)
- Heather HAUSENBLAS (Jacksonville University, USA)
- Tobias HAYER (University of Bremen, Germany)
- Susumu HIGUCHI (National Hospital Organization Kurihama Medical and Addiction Center, Japan)
- David HODGINS (University of Calgary, Canada)
- Eric HOLLANDER (Albert Einstein College of Medicine, USA)
- Jaeseung JEONG (Korea Advanced Institute of Science and Technology, Republic of Korea)
- Yasser KHAZAAL (Geneva University Hospital, Switzerland)
- Orsolya KIRÁLY (Eötvös Loránd University, Hungary)
- Emmanuel KUNTSCHE (La Trobe University, Australia)
- Hae Kook LEE (The Catholic University of Korea, Republic of Korea)
- Michel LEJOXEUX (Paris University, France)
- Anikó MARÁZ (Humboldt-Universität zu Berlin, Germany)
- Giovanni MARTINOTTI (‘Gabriele d’Annunzio’ University of Chieti-Pescara, Italy)
- Astrid MÜLLER (Hannover Medical School, Germany)
- Frederick GERARD MOELLER (University of Texas, USA)
- Daniel Thor OLASON (University of Iceland, Iceland)
- Nancy PETRY (University of Connecticut, USA)
- Bettina PIKÓ (University of Szeged, Hungary)
- Afarin RAHIMI-MOVAGHAR (Teheran University of Medical Sciences, Iran)
- József RÁCZ (Hungarian Academy of Sciences, Hungary)
- Rory C. REID (University of California Los Angeles, USA)
- Marcantanio M. SPADA (London South Bank University, United Kingdom)
- Daniel SPRITZER (Study Group on Technological Addictions, Brazil)
- Dan J. STEIN (University of Cape Town, South Africa)
- Sherry H. STEWART (Dalhousie University, Canada)
- Attila SZABÓ (Eötvös Loránd University, Hungary)
- Ferenc TÚRY (Semmelweis University, Hungary)
- Alfred UHL (Austrian Federal Health Institute, Austria)
- Róbert URBÁN (ELTE Eötvös Loránd University, Hungary)
- Johan VANDERLINDEN (University Psychiatric Center K.U.Leuven, Belgium)
- Alexander E. VOISKOUNSKY (Moscow State University, Russia)
- Aviv M. WEINSTEIN (Ariel University, Israel)
- Kimberly YOUNG (Center for Internet Addiction, USA)
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Apr 2023 | 0 | 6 | 4 |
| May 2023 | 0 | 8 | 8 |
| Jun 2023 | 0 | 8 | 7 |
| Jul 2023 | 0 | 11 | 9 |
| Aug 2023 | 0 | 28 | 6 |
| Sep 2023 | 0 | 21 | 9 |
| Oct 2023 | 0 | 0 | 0 |
Authors:
, , , , and
Authors:
, , , , and
Authors:
, , , , , , , , and
Authors:
, , , , and
Authors:
, , , , , and
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory